This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences

Life Sciences companies are experiencing a period of unprecedented change. Driven by shifts in age and demographics, disease, the entry of new technologies, and increased government regulations, life sciences companies will have to dramatically change in order to cope with the future industry environment.

The depth of Deloitte's global and local expertise in the area of life sciences enables us to provide clients with general as well as specific insights and forecasts of their environments. Our multidisciplinary functional expertise provides life sciences companies with made-to-measure support to meet the challenges they face.

More Featured insights

  • In the face of uncertainty: A challenging future for biopharmaceutical innovation
    The biopharmaceutical industry is in a precarious position regarding innovation: big bets in bold new areas are fraught with complexity and uncertainty, while success in mature therapeutic areas is becoming increasingly challenging.
  • The scientific information landscape and applications to translational research
    Investments made in biomedical and translational research have led to advancements in providing insights into the mechanisms and disease relevant markers that are implicated in human pathologies.
  • 2013 Global life sciences outlook: Optimism tempered by reality in a “new normal”
    Following years of growth and favourable market trends, the global life sciences industry now finds itself facing a challenging "new normal."

Contact our leader

Mohit Grover
Industry Leader
Life Sciences & Health Care

Learn more

  • ExternalURL
    Life sciences and health reform: No going back
    Tune into this episode of Deloitte Insights to learn more about the impact of health care reform on the life sciences industry
  • ExternalURL
    Value-based pharmaceutical pricing
    To transition from volume-based models to value-based pricing, companies must start with the basics
  • ExternalURL
    Advanced analytics: Good medicine for life sciences
    Learn more about the role of advanced analytics in the life sciences industry